All News

A study found no significant HRQOL differences between Erleada-based therapies and ADT plus AAP for advanced castration-sensitive prostate cancer.

Dr. Tycel Phillips discusses the FDA approval of a Calquence combo in MCL, making it the first and only BTK inhibitor approved for first line therapy.

Living with lymphoma for 15 years, I developed a concerning rash post-vacation, which led to a leukocytoclastic vasculitis diagnosis.

Researchers have published findings from the phase 2 LITESPARK-003 study of patients with previously untreated advanced clear-cell renal cell carcinoma.

Palliative care for young adults with colorectal cancer reduced invasive procedures, costs and increased DNR orders.

Dr. Alan Tan spoke with CURE® about what patients with kidney cancer and providers who treat it may be able to learn from ctDNA.

The recent American Cancer Society’s Cancer Statistics, 2025 report was released revealing a sobering trend for pancreatic cancer.

As we observe World Cancer Day, I’m reflecting on my own family’s experience with blood cancer.

Cancer rehab is a fairly new and growing specialty in the therapy world.

If you’re reading this, you recognize the importance of diet and nutrition after a cancer diagnosis.

Statistics show that breast cancer is most common in women over 50, but that doesn’t mean it can’t affect individuals outside that age range.

Join Triage Cancer for their free webinar on Post-Election Advocacy: Getting Engaged.

In resectable, locally advanced esophageal squamous cell carcinoma, neoadjuvant Tyvyt plus chemoradiotherapy led to an improvement in response rates.

Even stoics need to cry now and then. My advice from personal experience is this: it is okay to cry.

Dr. John Oertle discussed the significance of World Cancer Day, raising awareness about cancer care advancements and improving patient outcomes.

Alecensa weight gain is underreported in ALK+ NSCLC trials, highlighting the need for increased awareness and proactive management of this side effect.

Frontline treatment with Tevimbra plus irinotecan, paclitaxel, oxaliplatin and 5-FU/leucovorin had promising efficacy and manageable safety in gastric/GEJ cancer.

Dr. Filippo Pietrantonio discusses OrigAMI-1 trial data which assessed Rybrevant in mutated, wild-type, non-HER2-amplified metastatic colorectal cancer.

Breast cancer affected my looks and self-esteem, but I found small things could make a big difference in feeling pretty again.

Here is a select list of cancer therapies approved by the FDA throughout the month of January, featuring patient populations like AML, MDS and breast cancer.

Dr. Jonathan R. Strosberg, discussed results of the CABINET trial evaluating Cabometyx versus placebo in advanced gastrointestinal NETs.

Topline results from the COMPETE trial showed that ITM-11 met the study’s primary end point of PFS in inoperable, progressive grade 1 or grade 2 GEP-NETs.

After a second breast cancer diagnosis at 61, I faced 17 rounds of chemo, surgery and radiation, changing my perspective on life and leading to a new normal.

Early and late responders with esophageal squamous cell carcinoma experienced comparable OS benefits with Tevimbra plus chemo in the RATIONALE-306 trial.

A phase 3 trial is evaluating ASP-1929 photoimmunotherapy plus Keytruda in first-line treatment for recurrent head and neck squamous cell carcinoma.

BCG therapy is associated with a high frequency of side effects in NMIBC; however, when used in sequential combination with chemo, fewer were reported.

Hope is crucial for those of us with chronic lymphocytic leukemia, or any cancer, helping us navigate the disease's challenges.

From the reveal of NBA star Dwyane Wade’s cancer surgery to a Bachelorette star on her husband’s cancer diagnosis, here is this week’s top cancer news.